Asthma does not influence the severity of COVID-19: a meta-analysis

Ting Wu, MD*, Pengyi Yu, MD*, Yuanxiao Li, BD**, Junxin Wang, MD, C, Zhen Li, MD, D, Jingjing Qiu, MD, Limei Cui, PhD,*, Yakui Mou, MD and Yan Sun, PhD

Objective: Previous studies have reported a correlation between coronavirus disease-2019 (COVID-19) and asthma. However, data on whether asthma constitutes a risk factor for COVID-19 and the prevalence of asthma in COVID-19 cases still remain scant. Here, we interrogated and analyzed the association between COVID-19 and asthma.

Methods: In this study, we systematically searched PubMed, Embase, and Web of Science databases for studies published between January 1 and August 28, 2020. We included studies that reported the epidemiological and clinical features of COVID-19 and its prevalence in asthma patients. We excluded reviews, animal trials, single case reports, small case series and studies evaluating other coronavirus-related illnesses. Raw data from the studies were pooled into a meta-analysis.

Results: We analyzed findings from 18 studies, including asthma patients with COVID-19. The pooled prevalence of asthma in COVID-19 cases was 0.08 (95% CI, 0.06–0.11), with an overall I² of 99.07%, p<0.005. The data indicated that asthma did not increase the risk of developing severe COVID-19 (odds ratio [OR] 1.04 (95% CI, 0.75–1.46) p=0.28; I²=20%). In addition, there was no significant difference in the incidence of asthma with age in COVID-19 infections [OR] 0.77(95% CI, 0.59–1.00) p=0.24; I²=29%).

Conclusion: Taken together, our data suggested that asthma is not a significant risk factor for the development of severe COVID-19.

Introduction

The current outbreak of coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has greatly increased the global public health burden and mortality (1). The common clinical manifestation of COVID-19 includes dry cough and shortness of breath (2,3). As a chronic inflammatory disorder of the airways, asthma is characterized by a variety of respiratory symptoms (4), including wheezing, shortness of breath, and cough (5), which are highly similar to COVID-19. On the other hand, since fever, one of most common COVID19 symptoms, is a clinical symptom presented by any infection that exacerbates asthma, it is not a reliable clinical tool for the diagnosis of COVID-19. Therefore, it is conceivable that milder cases of COVID-19 might be confused with exacerbations of asthma, or the COVID-19 patients may have comorbidities that may also be associated with asthma. Thus, there is a compelling need to precisely dissect the relationship between COVID-19 and asthma.

There is some clinical data showing a higher prevalence of asthma among the patients with COVID19 (6). In humans, coronaviruses (CoVs) mainly cause respiratory tract infections (7), and viral respiratory infections are the most common trigger for severe asthma exacerbations in children and adults. Consequently, the European Academy of Allergy and Clinical Immunology (EAACI) Section on Pediatrics (8) and the Centers for Disease Control (CDC) (9) identified asthma as a significant risk factor for severe COVID-19 illness. Besides, a clinical study in the UK reported that asthma was a risk factor for COVID19 (10). On the contrary, epidemiologic studies have demonstrated a lower-than-expected prevalence of asthma in patients with COVID-19 (11–13). Broadhurst et al. discounted the idea that asthma is a risk factor for severe COVID-19 (14). Besides, in a systematic literature review, only two reports described asthma as a potential risk factor for COVID19 (15). Therefore, whether asthma constitutes a risk factor for COVID-19 is still unclear.

Identification of risk factors for the development of severe COVID-19 is critical to not only aid in the direct development of new treatments but also help in designing infection prevention strategies. Here, we aimed to assess whether asthma, one of most common chronic diseases, is a significant risk factor for developing severe COVID-19 and the prevalence of asthma in patients with COVID-19.
Methods

Search strategy and inclusion criteria

In this meta-analysis, we searched PubMed, Embase, and Web of Science databases for articles published from Jan 1, 2020 to August 28, 2020. We used the keywords “asthma” OR “wheeze” OR “wheezing” OR “recurrent wheezer” OR “recurrent wheezing” OR “acute wheeze” OR “wheezing episode” OR “asthma episode” OR “Bronchial Asthma” OR “Asthma, Bronchial disease 2019” OR “2019 novel coronavirus disease” OR “coronavirus 2019” OR “2019-nCoV” OR “SARS-CoV-2” OR “COVID 19” OR “coronavirus disease-19”. Additional articles were retrieved by screening the reference lists of the included studies. The literature search was restricted to articles published in English. Studies that investigated the epidemiology and clinical characteristics or features of COVID-19 were eligible.

Exclusion criteria

Records were managed with EndNote (version X9.0) to exclude duplicates. We excluded studies which did not describe asthma and COVID-19, those that did not show the epidemiological relationship between asthma and COVID-19 and those that evaluated only the relationship between COVID-19 and one symptom of asthma (e.g. wheezing). Reviews, non-English language and non-full text articles (e.g. editorials or congress abstracts) were also excluded.

Data extraction

We independently screened titles and abstracts of the potential studies; conflicts were resolved through discussion. We then independently read full-text articles to identify studies meeting the inclusion criteria, and the reference lists from all identified studies as well as reviews were scrutinized for inclusion. We extracted the following variables: author; date; study design; patient demographics; patients type; number of participants in severe and non-severe disease groups.

Data synthesis and statistical analysis

We calculated the pooled prevalence of asthma among the confirmed COVID-19 patients. Odds ratios (OR) were used to describe the probability of asthma occurrence in patients with severe versus non-severe COVID-19 and the younger versus the older. Due to heterogeneity within and between studies, a random-effects model was used to estimate the incidence Rate through Stata data analysis tools while the fixed-effects model was used to calculate the pooled ORs through the Mantel -Haenszel (M-H) method in Review Manager (version 5.3) tools. Both analysis tools provided a more conservative estimate of the 95% CI. Data were presented using forest plots. We examined between-study heterogeneity using the $F$ statistic. We defined COVID-19 severity as those, who were admitted to intensive care unit (ICU), needed mechanical ventilation or were at the verge of death.

Results

An initial search generated 690 potentially relevant papers, of which 333 duplications, 9 animal trials and 57 reviews were excluded in first screening of titles and abstracts. Then, 28 papers met the inclusion criteria. After more careful full-text review, additional 10 papers were excluded because they did not provide the relevant data about asthma ($n=2$), analyze the prognosis of COVID-19 ($n=2$), count the number of COVID-19 in asthmatic patients ($n=3$), or were documented case report ($n=1$), used the same database ($n=1$), and was a special paper ($n=1$). None of 1590 COVID-19 patients had physician-diagnosed asthma in the special paper (16). We postulated that this could be attributed to the fact that asthma symptoms are similar to COVID-19 symptoms (e.g. cough and shortness of breath); therefore, asthma patients were not evaluated. Meanwhile, this article is automatically excluded by using Stata software. Therefore, a total of 18 studies finally met the inclusion criteria and were included in our analysis (Figure 1), and the essential characteristics of the included studies are shown in Table 1.

Prevalence of asthma in confirmed COVID-19 cases

The 18 studies that included 3940 asthma patients reported a total of 41282 COVID-19 cases in their analyses. The pooled prevalence of asthma in the COVID-19 cases was 0.08 (95% CI, 0.06–0.11), with an overall $I^2$ of 99.07%, $p<0.005$ (Figure 2).

Disease severity among COVID-19-asthma patients

Only 5 of the 18 articles classified the COVID-19 patients as severe or non-severe. Five studies involving 279 asthma patients reported COVID-19 in their analyses. Approximately 19% (54/279) of the patients experienced severe COVID-19 disease compared to 81% (225/279) who exhibited non-severe symptoms. These data demonstrate that asthma patients are not at a higher risk of developing severe COVID-19 [calculated OR, 1.04 (95% CI, 0.75–1.46)]. The overall $I^2$ was 20%, $p=0.28$ (Figure 3).

The role of age in the incidence of asthma in COVID-19 patients

Three studies that involving 297 asthma patients reported the presence of COVID-19. A total of 54% of the asthma patients (159/297) reported were aged 50 years or less, while 46% patients (138/297) were more than 50 years. Thus, there was no demonstration of the incidence of asthma with age in COVID-19 [calculated OR, 0.77 (95% CI, 0.59–1.00)]. The overall $I^2$ was 29%, $p=0.24$ (Figure 4).

Discussion

Here, for the first time, we conduct a meta-analysis and provide an informed understanding of the relationship between asthma patients and COVID-19. This meta-analysis
demonstrated a pooled prevalence of asthma in COVID-19 patients and suggested that asthma patients are not predisposed to severe COVID-19 infections.

In compliance with our findings, CoVs, which are relatively harmful respiratory pathogens, have not been correlated with asthma which is a chronic inflammatory disorder of the airways where many cells (34) and cellular elements play a role and feature variable airway obstruction and bronchial hyperresponsiveness (35). Our pooled estimate of the prevalence of asthma in COVID-19 was 0.08 (95% CI, 0.06–0.11), which was almost similar to asthma in respiratory CoV from a previous study that reported a mean prevalence of 0.084 (95% CI, 0.051, 0.136) (36). In terms of clinical manifestations, clinical symptoms of

---

**Table 1.** Characteristic of the included studies.

| Author               | Date (Y-M) | Area                                      | Study type          | Sex (M/F) | Age   | Patient type                     | Score of Quality Evaluation Scale |
|----------------------|------------|-------------------------------------------|---------------------|-----------|-------|----------------------------------|-----------------------------------|
| Arentz et al. (17)   | 20-03      | Evergreen Hospital                        | Cross-Sectional     | 11/10     | 70(43–92) | Inpatients                   | 6 (11)                            |
| Argenziano et al. (18)| 20-05      | NYP/CUIMC electronic health record      | Case-Control       | 596/404   | 63(50–75) | Inpatients and outpatients    | 7 (9)                             |
| Avdeev et al. (19)   | 20-04      | Clinic of Pulmonology, Sechenov First Moscow State Medical | Cross-Sectional | –         | 62(34–83)  | Inpatients                   | 6 (11)                            |
| Beurnier et al. (20) | 2020       | Bicêtre Hospital, France                 | Cohort              | –         | 63(49–70)  | Inpatients                   | 5 (9)                             |
| Bhatraju et al. (21) | 20-03      | 9 Seattle-area hospitals                 | Cross-Sectional     | 15/9      | 64(23–97) | Inpatients and outpatients    | 9 (11)                            |
| Borobia et al. (22)  | 20-03      | La Paz University Hospital              | Case-Control       | 1074/1152 | 61(46–78) | Inpatients                   | 7 (9)                             |
| Cummings et al. (23) | 20-05      | 2 New York-presbyterian hospitals        | Cohort              | 171/86    | –      | Inpatients                   | 8 (9)                             |
| Docherty et al. (24) | 20-03      | Hospitals in England, Scotland, and Wales | Cohort              | 12068/8065 | 73(58–82) | Inpatients                   | 8 (9)                             |
| Duannu et al. (25)   | 20-01      | A medical center in Santa Clara County  | Case-Control       | 56/44     | 45(32–65) | Inpatients and outpatients    | 5 (9)                             |
| Garg et al. (26)     | 20-04      | 14 States in the USA                    | Cross-Sectional     | –         | >18    | Inpatients                   | 8 (11)                            |
| Gold et al. (27)     | 20-05      | The Georgia Department of Public Health, and eight Georgia hospitals | Case-Control       | 151/154   | 60(23–95) | Inpatients                   | 7 (9)                             |
| Goyal et al. (28)    | 20-04      | 2 Hospitals in New York City            | Case-Control       | 238/155   | 62.2(48.6–73.7) | Inpatients | 5 (9)                             |
| Li et al. (13)       | 20-04      | Tongji Hospital                         | Cohort              | 279/269   | 60(48–69) | Inpatients                   | 7 (9)                             |
| Lieberman-Cribbin et al. (29) | 2020 | Mount Sinai Health System | Case-Control | – | – | Inpatients and outpatients | 5 (9)                             |
| Mahdavinia et al. (30)| 20-04    | Rush University Medical Center           | Cross-Sectional     | 407/528   | >18     | Inpatients and outpatients    | 9 (11)                            |
| Richardson et al. (31)| 20-04   | Hospitals in Northwell Health           | Cohort              | 3437/2263 | 63(52–75) | Inpatients                   | 7 (9)                             |
| Song et al. (32)     | 2020      | Tongji Hospital                         | Case-Control       | 500/461   | 62(51–72) | Inpatients                   | 5 (9)                             |
| Zhang et al. (33)    | 2020      | Department of Allergology, Zhongnan Hospital of Wuhan University | Case-Control | 155/135  | 57(22–88) | Inpatients                   | 5 (9)                             |
COVID-19 (such as fever, cough, shortness of breath) on admission are also common in severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) patients. What’s more, SARS-CoV and MERS-CoV, belonging to respiratory CoV, did not appear to increase the risk of asthma exacerbations (36,37). To further investigate whether asthma is a risk factor for severe COVID-19, we performed subgroup analyses to establish the difference in the prevalence of asthma between patients with severe and non-severe COVID-19. The data showed no significant difference existed.

Figure 2. The forest plot of meta-analysis of asthma in COVID-19 cases.

Figure 3. The forest plot of meta-analysis of asthma in severe and non-severe COVID-19 cases.

Figure 4. The forest plot of meta-analysis of asthma with COVID-19 cases in different age group.
Although there is lack of concrete explanation, clinical manifestations of coronaviruses could be associated with the distribution of the angiotensin converting enzyme 2 (ACE2) in the respiratory airway epithelium. SARS-CoV-2 binds to the ACE2, a transmembrane endopeptidase that cleaves both angiotensin 1 and 2. ACE2 acted as a receptor for SARS-CoV. The downregulation of ACE2 during SARS-CoV2 infection is believed to contribute to the pathological changes in lungs (38). Furthermore, transmembrane peptidase serine 2 (TMPRSS2) and protease furin have been shown to be cofactors facilitating SARS-CoV-2 infectivity (39). It has been reported (40) that there were no differences in the expression levels of ACE2, TMPRSS2, or furin gene expression between healthy volunteers and people with mild-to-moderate and severe asthma. On the other hand, Jackson et al. (41) documented that respiratory allergy and controlled allergen exposures are associated with significant downregulation of ACE2, and the expression of ACE2 was lowest in those with both high levels of allergic sensitization and asthma. Meanwhile, IL-13, a type 2 cytokine, which is strongly related to allergic asthma, significantly reduced ACE2 expression (41). Chang et al. (42) proved the importance of the IL-13 in influenza-induced acute asthma exacerbations. In another study, Song et al. (32) showed that the number of ACE2 positive cells in bronchial and alveolar epithelial cells was increased in chronic obstructive pulmonary disease (COPD) patients, but reduced in asthmatic patients. In contrast to asthma, COPD increases the risks for severe COVID-19 among hospitalized patients (43). Besides, after normalizing for age, expression of the ACE2 has no significant differences in disease severity (41). Thus, age did not affect the incidence of asthma in COVID-19 patients.

In addition, inflammatory cytokine storm has recently been shown to contribute to the severe clinical manifestations and worse COVID-19 outcomes (13). Lymphocytopenia has been observed for COVID-19 patients with severe disease, while the neutrophil–lymphocyte ratio was proved to be an independent risk factor for increased mortality in COVID-19 patients with COPD (44). Compared to asthmatics, COVID-19 patients with COPD, especially those in severe condition, had higher levels of neutrophil percentage, C-reactive protein (CRP), and various inflammatory cytokines. However, asthmatic patients have mainly eosinophilia. In a mouse model study, the increased eosinophil levels in asthmatic airways may be one of the protective mechanisms from virus infection (45). Coupled with the above observations, our data demonstrated that asthma is not a significant risk factor for the development of severe COVID-19.

Conclusion

Taken together, asthma is not a significant risk factor for the development of severe COVID-19. Nevertheless, due to the novelty of COVID-19, we have to acknowledge our findings may be limited by insufficient study sample sizes. We suggest that future studies focused on respiratory allergy, asthma and, perhaps, other allergic disorders should provide insights into the impact of underlying allergies on COVID-19 susceptibility and disease severity.

Author’s contributions

YS, YM and YL conceived the study. YS, YM, TW, PY and YL created the study protocol. TW, PY, JW, ZL, JQ and LC reviewed the studies and extracted data. TW and PY drafted the first manuscript. All authors reviewed and approved the final manuscript. YS and YM are the guarantors for the overall contents of this manuscript.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. The intent of this policy is not to prevent authors with these relationships from publishing work, but rather to adopt transparency such that readers can make objective judgments on conclusions drawn.

References

1. WHO Coronavirus disease (COVID-2019) Situation Report. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
2. Shaker MS, Oppenheimer J, Grayson M, Stukus D, Hartog N, Hsieh EWY, Rider N, Dutmer CM, Vander Leek TK, Kim H, et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. J Allergy Clin Immunol Pract. 2020;8(5):1477–1488.e5. doi:10.1016/j.jaip.2020.03.012.
3. Lovato A, de Filippis C. Clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 2020;99(9):569–576. doi:10.1177/01455613209202762.
4. Kowalski ML, Agache I, Bavek S, Baktiras A, Blanca M, Bocheneck G, Bonini M, Heffler E, Klimek L, Laidlaw TM, et al. Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)-a EAACI position paper. Allergy. 2019;74(1):28–39. doi:10.1111/all.13599.
5. He Z, Feng J, Xia J, Wu Q, Yang H, Ma Q. Frequency of signs and symptoms in persons with asthma. Respir Care. 2020;65(2):252–264. doi:10.4187/respcare.06714.
6. Licskai C, Yang CL, Ducharme FM, Radhakrishnan D, Podger D, Ramsey C, Samanta T, Côté A, Madhavani M, Lougheed MD. Key highlights from the Canadian Thoracic Society Position statement on the optimization of asthma management during the coronavirus disease 2019 pandemic. Chest. 2020;158(4):1335–1337. doi:10.1016/j.chest.2020.05.551.
7. Bergmann CC, Silverman RH. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies. CCJM. 2020;87(6):321–327. doi:10.3949/ccjm.87a.20047.
8. Brough HA, Kalayci O, Sediva A, Untersmyr E, Munblit D, Rodriguez Del Rio P, Vazquez-Ortiz M, Arasi S, Alvaro-Lozano M, Isabouri S, et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics. Pediatr Allergy Immunol. 2020;31(5):442–448. doi:10.1111/pai.13262.
9. Garcia M, Lipskiy N, Tyson J, Watkins R, Esser ES, Kinley T. Centers for Disease Control and Prevention 2019 novel coronavirus disease (COVID-19) information management: addressing
national health-care and public health needs for standardized data definitions and codified vocabulary for data exchange. J Am Med Inform Assoc. 2020;27(9):1476–1487. doi:10.1093/jamia/oca141.

10. Williamson EL, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Ingleby P, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436. doi:10.1038/s41586-020-2521-4.

11. Lupia T, Scabini S, Morneze Pinna S, Di Perri G, De Rosa FG, Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak: a new challenge. J Glob Antimicrob Resist. 2020;21:22–27. doi:10.1016/j.jgar.2020.02.021.

12. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7):1730–1741. doi:10.1111/all.14238.

13. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. doi:10.1016/j.jaci.2020.04.006.

14. Broadhurst R, Peterson R, Wisnivesky JP, Federman A, Zimmer SM, Sharma S, Wechsler M, Holguin F. Asthma in COVID-19 hospitalizations: an underestimated risk factor? Ann Am Thorac Soc. 2020;17(12):1645–1648. doi:10.1513/AnnalsATS.202006-613RL.

15. Castro-Rodriguez JA, Forno E. Asthma and COVID-19 in children: A systematic review and call for data. Pediatr Pulmonol. 2020;55(9):2412–2418. doi:10.1002/ppul.24909.

16. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020.

17. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. doi:10.1016/j.jaci.2020.04.006.

18. Broadhurst R, Peterson R, Wisnivesky JP, Federman A, Zimmer SM, Sharma S, Wechsler M, Holguin F. Asthma in COVID-19 hospitalizations: an underestimated risk factor? Ann Am Thorac Soc. 2020;17(12):1645–1648. doi:10.1513/AnnalsATS.202006-613RL.

19. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. doi:10.1016/j.jaci.2020.04.006.

20. Broadhurst R, Peterson R, Wisnivesky JP, Federman A, Zimmer SM, Sharma S, Wechsler M, Holguin F. Asthma in COVID-19 hospitalizations: an underestimated risk factor? Ann Am Thorac Soc. 2020;17(12):1645–1648. doi:10.1513/AnnalsATS.202006-613RL.

21. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. doi:10.1016/j.jaci.2020.04.006.

22. Broadhurst R, Peterson R, Wisnivesky JP, Federman A, Zimmer SM, Sharma S, Wechsler M, Holguin F. Asthma in COVID-19 hospitalizations: an underestimated risk factor? Ann Am Thorac Soc. 2020;17(12):1645–1648. doi:10.1513/AnnalsATS.202006-613RL.

23. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763–1770. doi:10.1016/S0140-6736(20)31189-2.

24. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, et al. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. doi:10.1136/bmj.m1985.

25. Duanmu Y, Brown IP, Gibb WR, Singh J, Matheson LW, Blomkalns AL, Govindarajan P. Characteristics of emergency department patients with COVID-19 at a single site in Northern California: clinical observations and public health implications. Acad Emerg Med. 2020;27(6):505–509. doi:10.1111/acem.14003.

26. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Prill M, Chai SJ, Kirey PD, Alden NB, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NEIT, 14 States, March 1–30, 2020. MMWR Mortal Wkly Rep. 2020;69(15):458–464. doi:10.15585/mmwr.mm6915e3.

27. Gold AW, Wong KK, Patel PR, Rossow J, da Silva J, Natarajan P, Morris SB, Fanfair RN, Rogers-Brown J, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 – Georgia, March 2020. MMWR Mortal Wkly Rep. 2020;69(18):545–550. doi:10.15585/mmwr.mm6918e1.

28. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen J, Rabj Ri, Satlin MJ, Campion TR, Jr., Nahid M, Ringel JB, et al. Clinical characteristics of COVID-19 in New York City. N Engl J Med. 2020;382(24):2372–2374. doi:10.1056/NEJMc2010419.

29. Lieberman-Cribbin W, Rapp J, Alpert N, Tuminello S, Taioli E. The impact of asthma on mortality in patients with COVID-19. Chest. 2020;158(6):2290–2291. doi:10.1016/j.chest.2020.05.575.

30. Mahdavinia M, Foster KJ, Jauregui E, Moore D, Adnan D, Andy-Nweye AB, Khan S, Bishehsari F. Asthma prolongs intubation in COVID-19. J Allergy Clin Immunol Pract. 2020;8(7):2388–2391. doi:10.1016/j.jaip.2020.05.006.

31. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, the Northwell COVID-19 Research Consortium, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775.

32. Song J, Zeng M, Wang H, Qin C, Hou HY, Sun ZY, Xu SP, Wang GP, Guo CL, Deng YK, et al. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy. 2021;76(2):483–496. doi:10.1111/all.14517.

33. Zhang JJ, Cao YY, Dong X, Wang BC, Liao MY, Lin J, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan. Allergy. 2020;75(7):1730–1741. doi:10.1111/all.14238.

34. National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma (EPR-3). 2007. http://www.nhlbi.nih.gov/guidelines/asthma/index.htm.

35. Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5(S1):S2–S6. doi:10.1002/air.21609.

36. Zheng XY, Xu YJ, Guan WJ, Lin LF. Regional, age and respiratory-secretion-specific prevalence of respiratory viruses
associated with asthma exacerbation: a literature review. Arch Virol. 2018;163(4):845–853. doi:10.1007/s00705-017-3700-y.
37. Van Bever HP, Chng SY, Goh DY. Childhood severe acute respiratory syndrome, coronavirus infections and asthma. Pediatr Allergy Immunol. 2004;15(3):206–209. doi:10.1111/j.1399-3038.2004.00137.x.
38. Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J. 2010;74(3):405–410. doi:10.1253/circj.CJ-10-0045.
39. Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. Embo J. 2020;39(10):e105114. doi:10.15252/embj.20105114.
40. Bradding P, Richardson M, Hinks TSC, Howarth PH, Choy DF, Arron JR, Wenzel SE, Siddiqui S. ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma-implications for COVID-19. J Allergy Clin Immunol. 2020;146(1):208–211. doi:10.1016/j.jaci.2020.05.013.
41. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, Visness CM, Durham SR, Larson D, Esnault S, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146(1):203–206.e3. doi:10.1016/j.jaci.2020.04.009.
42. Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, Dekruyff RH, Uematsu DT. In innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011;12(7):631–638. doi:10.1038/ni.2045.
43. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020;167:105941. doi:10.1016/j.rmed.2020.105941.
44. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768. doi:10.1093/cid/ciaa248.
45. Sabogal Piñeros YS, Bal SM, Dijkhuis A, Majoor CJ, Dierdorf BS, Dekker T, Hoeftsfart EP, Bonta PI, Picavet D, van der Wel NN, et al. Eosinophils capture viruses, a capacity that is defective in asthma. Allergy. 2019;74(10):1898–1909. doi:10.1111/all.13802.